drugset / Trial / NCT02172573
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as comparators in a double-blind design (phase III comparative study).
Timeline
- Start
- 1999-04
- Primary completion
- 2000-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bromocriptine | Small molecule | 22.5 mg | Oral |
| Subject | Pramipexole | Unknown | 4.5 mg | Oral |